Neurocrine Biosciences, Inc. presented new data from the open-label KINECT-HD2 study demonstrating an established long-term safety profile, tolerability and sustained improvements in chorea severity through three years of… read more.
Neurocrine Biosciences, Inc. announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia on patients and… read more.
Neurocrine Biosciences, Inc. presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily Ingrezza (valbenazine) capsules…. read more.
Neurocrine Biosciences, Inc. announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement,… read more.
Neurocrine Biosciences, Inc. announced the FDA approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years… read more.
Neurocrine Biosciences, Inc. announced the FDA has approved Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated with Huntington’s disease (HD). Ingrezza is the only selective… read more.
Neurocrine Biosciences, Inc. presented findings from a meta-analysis of three long-term studies evaluating Ingrezza (valbenazine) capsules that demonstrated substantial and sustained improvements in tardive dyskinesia (TD) in adults… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
